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Ubiquitin, the peptide ‘tag’ that targets eukaryotic
proteins for degradation by the proteasome, has also
been implicated in transcriptional activation. The
mechanism of gene activation might include recruit-
ment of a transcriptional elongation factor by ubiqui-
tinated activators.
Transcriptional activation in eukaryotes is a highly
regulated process requiring the concerted interactions
of DNA-binding transcriptional activators, general tran-
scription factors and coactivator proteins to stimulate
the recruitment or activity of RNA polymerase II at the
appropriate gene promoters in response to biological
signals. Activators are often unstable proteins, which
may be one way to maintain tight control over their
function. Ubiquitination of activators can lead to their
destruction by the proteaseome, but might also func-
tion in the transcriptional activation event itself [1,2]. A
recent report in Current Biology by Kurosu and Peterlin
[3] offers an explicit mechanism for the role of ubiquitin
in the stimulation of transcriptional elongation.
Some transcriptional activators stimulate trans-
criptional initiation by recruiting general transcription
factors and RNA polymerase II into a preinitiation
complex. Other activators foster the release of RNA
polymerase II from the promoter, or boost the elonga-
tion rate through the transcribed gene [4]. For example,
the activation domains of the HIV Tat and the her-
pesvirus VP16 proteins can interact with P-TEFb, a
protein complex required for the suppression of
pausing of RNA polymerase II [5]. P-TEFb comprises a
C-type cyclin (most often CycT1) and a cyclin-depen-
dent kinase (Cdk9) [5], and can phosphorylate the
carboxy-terminal domain (CTD) of the largest subunit of
RNA polymerase II and also certain negative elongation
factors. These phosphorylation events allow efficient
elongation and also help recruit the RNA processing
proteins that travel with RNA polymerase II for cotrans-
lational processing of the nascent mRNA [6,7].
Transcription activators are tightly regulated through
diverse mechanisms that control subcellular localiza-
tion, protein stability and protein activity, often medi-
ated by post-translational modifications such as
phosphorylation, acetylation, glycosylation and
ubiquitination. Ubiquitin is a polypeptide of 76 amino
acids that typically gets covalently attached to proteins
destined for destruction by the proteasome (reviewed
in [8,9]). Many transcriptional activators are unstable
proteins degraded by the ubiquitin–proteasome
pathway [1,10]. This instability is often used to restrain
the activity of an activator at times when its target
genes should not be expressed, or to quench its activ-
ity so that the transcriptional response to a stimulus
can be quickly dampened. Interestingly, the activation
domains of many regulatory proteins overlap with the
signals responsible for the degradation [2,10,11],
leading to the suggestion that destruction of the acti-
vator might be a requisite step in the mechanism of
transcriptional activation [1].
Additional evidence suggests that the proteasome
itself can be intimately involved in transcriptional
activation. The yeast Sug1 protein, a component of the
19S subcomplex of the proteasome, exhibits coactiva-
tor properties in the activation of galactose regulated
genes [12]. Proteasome components have been
detected at actively transcribed genes using chromatin
immunoprecipitation assays [13,14]. Turnover of the
estrogen receptor by the proteasome is important for
estrogen-regulated transcription [14,15]. Some genetic
experiments implicate the proteasome specifically in
transcriptional elongation [16]. The proteasome (or parts
thereof) may help reorganize or disassemble the pre-
intiation complex, freeing RNA polymerase II to
progress into elongation. In this context, the protea-
some might not be executing its proteolytic function
[17], but might instead use its ATPases as chaperones
for remodeling protein conformations or interactions. 
Indeed, ubiquitination does not always presage
destruction. Non-degradative functions of ubiquitin
have emerged in recent years, including regulation of
protein location, protein function, and protein–protein
interactions [18]. Several reports suggest that such
nonproteolytic functions are important for the activity of
transcriptional activation domains from the VP16 and
Tat proteins [19,20]. In these studies, the function of a
given activator protein was diminished in cells lacking
the appropriate ubiquitin ligase — which attaches ubiq-
uitin to specific target proteins — but the transcriptional
function was restored by genetically fusing the ubiqui-
tin polypeptide to the activator protein.
Kurosu and Peterlin [3] report evidence suggesting
an explicit mechanism by which ubiquitination of
activators might facilitate transcriptional elongation.
They constructed chimeric genes joining the activation
domain of VP16 — wild-type or mutant versions —
with either the LexA DNA-binding domain (LexA–VP16)
or the RNA-binding domain of the HIV Rev protein
(Rev–VP16). When the fusion proteins bearing the
wild-type VP16 activation domain were expressed in
mammalian cells, they were ubiquitinated and they
stimulated expression of cognate reporter genes.
Three aspects of these experiments suggest that
transcriptional elongation was boosted. First, the
activation was observed using either a DNA-based
tether (LexA binding to a promoter sequence) or an
RNA-based tether (Rev binding to an initial portion of
the reporter gene transcript). Second, the stimulation
was blocked by a dominant-negative form of the Cdk9
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protein, indicating that the transcriptional activation
depended on P-TEFb. And third, use of the mutant
VP16 domain resulted in less abundant expression of
distal regions of the reporter gene relative to more
proximal segments, suggesting pausing or premature
termination of transcription.
The real news derives from additional experiments
that point quite directly to a role for ubiquitin in this
transcriptional elongation activity. When ubiquitin was
artificially fused to LexA–VP16 — generating
ubiquitin–LexA–VP16 — expression of the reporter
gene was augmented and the deleterious effect of the
VP16 F442A mutation was suppressed. LexA–VP16
was shown to bind to the CycT1 subunit of P-TEFb in
vitro, and ubiquitin–LexA–VP16 bound even more
avidly to CycT1. In fact, VP16 and ubiquitin bound to
different regions of CycT1, so when both are present
the interaction is stronger. The model that emerges is
that the presence of ubiquitin attached to an activator
protein results in enhanced recruitment of P-TEFb and
thus enhanced transcriptional elongation (Figure 1).
One caveat for these experiments arises from the use
of highly artificial fusion proteins and reporter genes,
and so it will be important to test this hypothesis in
more native biological contexts. Nonetheless, the
strength of the new report by Kurosu and Peterlin [3] is
their identification of a mechanistic and testable
hypothesis for the function for the ubiquitin that gets
attached to transcriptional activator proteins. In
showing that this ubiquitin augments binding of the P-
TEFb elongation factor and enhances synthesis of full-
length transcripts, this model connects the
ubiquitination of acidic activators with the ability to
stimulate transcriptional elongation. This will not be the
only mechanism for transcriptional activation; other
classes of activators with glutamine-rich or proline-rich
activation domains are not ubiquitinated [10] and do
not stimulate transcriptional elongation [4]. And it also
may not be the only role that ubiquitin plays in tran-
scriptional activation; other mechanisms, particularly
those that invoke the proteasome as an active partici-
pant, may also emerge. But the biochemical hypothesis
proposed by Kurosu and Peterlin [3] provides an inter-
esting focus for future experiments. 
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Figure 1. Ubiquitination and the control of transcription.
(A) Ubiquitination of an activator protein can be triggered by an
acidic activation domain (AD). (B) The ubiquitin moiety and the
AD itself can bind simultaneously to distinct regions of the
CycT1 component of P-TEFb. (C) The Cdk9 subunit of P-TEFb
then phosphorylates Ser residues in the carboxy-terminal tail of
the large subunit of RNA polymerase II, resulting in 
(D) enhanced elongation efficiency and recruitment of RNA-pro-
cessing enzymes.
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